Cancer chemotherapy and pharmacology
-
Cancer Chemother. Pharmacol. · Jan 2012
Meta Analysis Comparative StudyMeta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.
To compare docetaxel-based doublet with single-agent docetaxel as second-line treatment in non-small-cell lung cancer (NSCLC). ⋯ This was the first meta-analysis of docetaxel-based doublet versus single-agent docetaxel as second-line therapy in the treatment of non-small-cell lung cancer. The results indicated that docetaxel-based doublet therapy did not gain any benefit in survival but significantly improved PFS and better ORR versus single-agent docetaxel. However, more incidences of grade 3 or 4 neutropenia, thrombocytopenia, and diarrhea were observed in docetaxel-based doublet group.
-
Cancer Chemother. Pharmacol. · Jun 2009
Meta AnalysisPopulation pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects.
To characterize the population pharmacokinetics of plitidepsin (Aplidin) in cancer patients. ⋯ The integration of phase I/II pharmacokinetic data demonstrated plitidepsin linear elimination from plasma, dose-proportionality up to 8.0 mg/m(2), and time-independent pharmacokinetics. The distribution to red blood cells can be considered linear at doses lower than 5 mg/m(2) administered as 3-h or longer infusion. No clinically relevant covariates were identified as predictors of plitidepsin pharmacokinetics.